Lasa Supergenerics Ltd expands Manufacturing Capacity of API Albendazole to meet Global Demand

Lasa Supergenerics Ltd, a leading innovator in the animal and human healthcare value chain, is pleased to announce the successful expansion of its manufacturing capacity for Albendazole USP. This enhancement was achieved through strategic debottlenecking of existing infrastructure and the installation of new machinery at its manufacturing facility.

This expansion strengthens Lasa's ability to meet increasing demand for Albendazole across domestic and international markets, reaffirming its position as a trusted supplier of highquality Active Pharmaceutical Ingredients (APIs), The Expansion will further achieve Increased Capacity of Albendazole USP, Improve Product Efficiency and reduce lead time, enhance global supply capacity with adherence to top-tier quality and standards.

With the said Expansion the Total capacity is anticipated to represent a growth of 20%.

This expansion is supported by a capital investment (CAPEX) of nearly Rs. 100.00 Lakhs which is already deployed and additional will be deployed over the time.

Dr. Omkar Herlekar, Chairman and Managing Director of the Company, said, with our vision we are thrilled to announce this significant expansion of our Albendazole USP manufacturing capacity. It underscores our dedication to supporting our customers and fortifying our role as a reliable API supplier in the pharmaceutical industry."

Shares of Lasa Supergenerics Limited was last trading in BSE at Rs. 17.90 as compared to the previous close of Rs. 17.97. The total number of shares traded during the day was 25342 in over 233 trades.

The stock hit an intraday high of Rs. 18.62 and intraday low of 17.80. The net turnover during the day was Rs. 457914.00.

Source : Equity Bulls

Keywords

LasaSupergenerics INE670X01014 ManufacturingCapacity Expansion APi Albendazole